Navigation Links
Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV,Activity

Rigel Program to be Presented at Keystone Scientific Meeting

SOUTH SAN FRANCISCO, Calif., March 27, 2007 /PRNewswire-FirstCall/ -- Rigel today announced that Yonchu Jenkins, Ph.D., Associate Director of Virology, will be presenting on the company's efforts to develop a small molecule therapeutic to treat patients with the Human Immunodeficiency Virus (HIV) infection at the Keystone Symposium in British Columbia on March 27th and 29th. Dr. Jenkins will present both a poster and an oral presentation entitled, the Identification of Novel Antiretroviral Compounds by Targeting HIV Vif Function.

Dr. Jenkins and her colleagues at Rigel are investigating ways to inhibit Vif, a specific viral protein produced by HIV that is essential for its replication. Inside HIV-infected cells, the invading protein, Vif, neutralizes the potent anti-viral activity of a host human protein called Apobec3G. By recruiting Apobec3G into an ubiquitin ligase complex, Vif enables the subsequent degradation of Apobec3G, thus eradicating it from HIV-infected cells. When Vif is absent, Apobec3G's potent anti-viral activity renders HIV virus particles non-infectious. Rigel is exploring a number of small molecule compounds aimed at modulating the intracellular ubiquitin ligase signaling pathways utilized by Vif so that Apobec3G will remain active in the presence of HIV and impede the virus from replicating.

"Our approach focuses on restoring the body's natural ability to fight the virus by means of a ubiquitin ligase target. By focusing on a host target, rather than a viral target we may create a new class of anti-retroviral therapeutics," said Donald G. Payan, M.D., Executive Vice President and Chief Scientific Officer of Rigel. "Rigel is uniquely positioned to pursue this target given our extensive experience in the ubiquitin ligase field and in the virology area," he added.

For further information on Rigel's HIV program, Dr
'"/>




Page: 1 2 3

Related medicine technology :

1. Rigel to Present New Research Programs at AACR Meeting
2. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
5. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
6. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
7. Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007
8. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
9. CuraGen Presents Update on Clinical Development Program for Belinostat
10. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
11. Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program
Post Your Comments:
(Date:7/28/2014)... 2014 KaloBios Pharmaceuticals, Inc. (Nasdaq: ... of the KB001-A development program, including an update on ... KB001-A Collaboration Update KaloBios announced that ... regain all rights to KaloBios, KB001-A program. Under this ... 2010 has been terminated. Under that collaboration agreement, Sanofi ...
(Date:7/28/2014)... July 28, 2014  Serco Inc., a provider ... Company has been awarded a re-compete contract to ... and its Deployable Medical Systems.  Serco will provide ... to provide world-class healthcare to meet warfighter and ... the globe. The five year contract has a ...
(Date:7/28/2014)... Colo. , July 28, 2014  Array ... financial results for the fourth quarter and ... a conference call to discuss those results ... Chief Executive Officer and Michael Carruthers ... call.Conference Call InformationDate:Tuesday, August 12, 2014Time:9:00 a.m. ...
Breaking Medicine Technology:KaloBios Provides Update on KB001-A Partnership and Clinical Status 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 3KaloBios Provides Update on KB001-A Partnership and Clinical Status 4KaloBios Provides Update on KB001-A Partnership and Clinical Status 5KaloBios Provides Update on KB001-A Partnership and Clinical Status 6Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... -First Combination Study of a MET and EGFR Inhibitor-, ... (Nasdaq: EXEL ) today announced that it has ... non-small cell lung cancer (NSCLC) who have had,progressive disease ... a small molecule that simultaneously inhibits the MET, RET ...
... ASHBURN, Va., Jan. 4 Innocoll, Inc., ... first of a series of,planned phase 2 ... subsidiary,Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE ... has commenced dosing., Innocoll,s BUPIVACAINE SURGICAL ...
Cached Medicine Technology:Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 2Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 3Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 4Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4
(Date:7/28/2014)... Camp Soaring Eagle today announced it ... Cornville, AZ. The nonprofit organization, founded in July ... to attend medically supervised camps at no cost ... a variety of programs to Arizona families and ... illnesses including: Illness Specific Camping Weekends, Illness Specific ...
(Date:7/28/2014)... WI (PRWEB) July 28, 2014 Quincy ... Prevagen® , is pleased to announce the release of ... by company president and co-founder Mark Underwood. , The ... health information, offering useful techniques for readers to improve ... as an unavoidable conclusion, The Brain Health Guide provides ...
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... know it takes humans just milliseconds to look at someone,s ... a new study finds that certain facial features seem to ... The shape and size of the mouth, for example, appear ... are keys to attractiveness. The study findings suggest ...
(Date:7/28/2014)... Ticket Down is reliable source for ... TX at the Cotton Bowl. The 2014 Guinness International ... it is an eight team tourney. The tournament participants ... from La Liga, Serie A, English Premier League, and Superleague ... on the pitch include: Manchester United, Manchester City, Olympiacos, ...
(Date:7/28/2014)... Glutamine is the most abundant single ... be conditionally essential during times when the body undergoes ... & Immune System Support. , Having a heavy work ... supplementing with additional glutamine may be advantageous. Glutamine supplementation ... body, digestion and immune system function. Stress on the ...
Breaking Medicine News(10 mins):Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3
... ADHD who carry a specific type of dopamine ... (MPH) than those without the genotype, according to ... The findings come from the first-ever placebo-controlled ... school age children to evaluate variants of the ...
... took the banned substance were leaner and ran faster, ... hormone, a substance frequently implicated in sports doping scandals, ... shows. , Australian researchers gave 96 non-professional athletes aged ... saline placebo. Participants included 63 men and 33 women. ...
... NEW ORLEANS, LA (May 3, 2010) Researchers have ... bowel disease, while other science shows that intra-abdominal fat ... patients, and new technology shows promising results for improvements ... the studies being presented at Digestive Disease Week (DDW) ...
... 2010) The results of new research results published ... the American College of Surgeons show that a ... hospital surgical ward. Postoperative pneumonia is a ... most common infectious complication after urinary tract and wound ...
... and without symptoms, screening mammography may be inappropriate, researchers say ... under the age of 40 result in many return visits ... a new study finds. , Almost 30 percent of ... getting mammograms, although they,re not generally recommended until age 40. ...
... later outcomes, studies show , MONDAY, May 3 (HealthDay ... critical prenatal, maternal and environmental factors can be in shaping ... things, the studies found that kids who stayed glued to ... who smoked or took antidepressants during pregnancy had raised risks ...
Cached Medicine News:Health News:Research helps end guesswork in prescribing ADHD drug 2Health News:Human Growth Hormone Does Boost Athletic Performance 2Health News:Human Growth Hormone Does Boost Athletic Performance 3Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 2Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 3Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 4Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 5Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 6Health News:Surgeons' pilot prevention program reduces incidence of postoperative pneumonia 2Health News:Effects of TV, Drug Exposures in Early Life May Be Long-Lasting 2Health News:Effects of TV, Drug Exposures in Early Life May Be Long-Lasting 3
... ORTHOSTAR table is the most ... It was designed for both ... traction with an integrated shoulder ... special purpose operating table for ...
... theatre is ready for all current and future ... design allows a quick, problem-free conversion to meet ... connected securely and sturdily to MARS through a ... should ever be a problem in spite of ...
... Exclusive, 210° Top Rotation provides ... purpose surgery. The Hercules 6700B eliminates ... during head-end procedures, while providing ample ... to sit during procedures. Removable back ...
... schaereraxis 200/300 product range includes ... been designed for the varied ... in the surgical practice, in ... A favorable price-performance ratio takes ...
Medicine Products: